Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context
Yifan Deng, Spencer S. Ericksen, Anthony Gitter · 2025
Read Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context by Yifan Deng, Spencer S. Ericksen, Anthony Gitter (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-12574.txt.
Introduction
Yifan Deng, Spencer S Ericksen, and Anthony Gitter present a 2025 paper on Assay2Mol, a workflow that uses a large language model to design new drug molecules. Rich records from past lab screening tests hold text about targets and test methods, but that text sat unused because it has no fixed format. The workflow puts those records to work.
Given a new disease target, the system pulls records of tests on similar targets and feeds them to the model as examples. The model then proposes candidate molecules. The authors report that their method beats recent machine learning tools that design from protein shape alone, and that its molecules look easier to make in a lab.
Catalog record
| CREATOR | Yifan Deng, Spencer S. Ericksen, Anthony Gitter |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2507-12574
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context Yifan Deng, Spencer S. Ericksen, Anthony Gitter Abstract Scientific databases aggregate vast amounts of quantitative data alongside descriptive text. In biochemistry, molecule screening assays evaluate the functional responses of candidate molecules against disease targets. Unstructured text that describes the biological mechanisms through which these targets operate, experimental screening protocols, and other attributes of assays offer rich information for new drug discovery campaigns but has been untapped because of that unstructured format. We present Assay2Mol, a large language model-based workflow that can capitalize on the vast existing biochemical screening assays for early-stage drug discovery. Assay2Mol retrieves existing assay records involving targets similar to the new target and generates candidate molecules using in-context learning with the retrieved assay screening data. Assay2Mol outperforms recent machine learning approaches that generate candidate ligand molecules for target protein structures, while also promoting more synthesizable molecule generation. 1 Introduction Early-stage drug development and target validation typically involve a search through chemical space for drug-like molecules that perturb a target of interest, usually a protein activity connected to a disease condition. For a new target, the search starts with assay development and scaling for high-throughput testing in order to experimentally screen a pre-defined chemical library for active molecules. From data obtained on screens of a target of interest (or related targets), computational models can learn structure-activity relationships that inform selection of new molecules for testing. Public screening data repositories like PubChem ( Kim et al. 2024 ) and ChEMBL ( Mendez et al. 2018 ) possess great value in this regard. PubChem now contains 1.77 million assay records (BioAssay records) comprising \sim 300 million bioactivity outcomes across \sim 250,000 protein targets and 1,000s of cell lines 1 1 1 https://pubchem.ncbi.nlm.nih.gov/docs/statistics . BioAssay records are richly annotated with chemicals tested, target genes, pathways, proteins, cell lines, publications, patents, related BioAssay records, tabular molecule testing results, text descriptions of assay format, protocols, and relevance to disease states. Sorting through these repositories for the data pertinent to an arbitrary target is a daunting task. Scientists need workflows that can rapidly identify relevant BioAssay records based on their associated text, extract key textual and tabular chemical testing data comprising molecule structures paired with experimental activity outcomes, and apply this information to models capable of learning structure-activity relationships to recommend new molecules for testing. Given the extensive descriptive text components in BioAssay records, leveraging natural language processing capabilities becomes crucial for efficient retrieval and interpretation. Large language models (LLMs), with their advanced ability to process and interpret unstructured text, are well-suited for assessing BioAssay relevance by extracting key experimental details and identifying meaningful activity patterns. LLMs have demonstrated great ability in different kinds of tasks including translation, multi-round conversation, and so on. LLMs are also adept in biology and chemistry related tasks, for example, molecule property prediction, and text-guided molecule generation. LLMs support in-context learning, which extends to scientific domains. GPT-3 ( Brown et al. 2020 ) highlights the ability of LLMs to adapt to new tasks with minimal examples. In text-guided molecule design, GPT-4 outperforms other fine-tuned models with few-shot in-context learning. ( Zhao et al. 2024 ; Guo et al. 2023 ) This raises the question of whether LLMs can support different strategies for molecule design. Beyond generating molecules that satisfy specified property constraints, can LLMs navigate unstructured text within public BioAssay records and then use them as context to design molecules with functional properties, such as protein inhibition? We propose Assay2Mol to maximize the use of BioAssay records with LLMs. Given input such as protein target descriptions, phenotypic data, or other textual information, Assay2Mol retrieves relevant BioAssays and leverages in-context learning to generate new molecules with the desired biological activity (Figure 1 ). Our contributions can be summarized as follows: • We introduce Assay2Mol, an LLM-based drug design workflow that retrieves relevant PubChem BioAssay data for a given query and then learns to generate new candidate molecules from this assay context. • Unlike structure-based drug discovery (SBDD) methods, Assay2Mol does not require protein structures or even sequences. It can even generate active molecules for cell-based and phenotypic assays and endpoints (e.g., tumor shrinkage, cardiotoxicity, QT interval prolongation). • Because Assay2Mol relies on LLMs that are pretrained on chemical data for its molecule generation, the output molecules can be more like "retrieval" rather than de novo "generation". This makes the generated molecules chemically plausible and synthetically accessible. Figure 1: The Assay2Mol workflow. A chemist provides a target description, which is used to retrieve BioAssays from the pre-embedded vector database. After filtering for relevance, the BioAssays are summarized by an LLM. The BioAssay ID is then used to retrieve experimental tables. The final molecule generation prompt is formed by combining the description, summarization, and selected test molecules with associated test outcomes, enabling the LLM to generate relevant active molecules. The icons come from Flaticon.com and svgrepo.com 2 Related work 2.1 Large Language Models in biochemistry LLMs are an alternative to biomolecular sequence- or structure-based models for learning structure-activity or structure-property relationships. Multimodal molecule and text generation ( Edwards et al. 2021 ; Pei et al. 2024 ; Deng et al. 2024 ; Zhao et al. 2024 ; Fang et al. 2023 ) , in-context learning for chemistry ( Fifty et al. 2023 ; Jablonka et al. 2024 ; Nguyen and Grover 2024 ; Moayedpour et al. 2024 ; Schimunek et al. 2025 ) , and LLM agents ( M. Bran et al. 2024 ; McNaughton et al. 2024 ; Swanson et al. 2024 ; Gao et al. 2025 ; Liu et al. 2025 ; Wei et al. 2025 ) are at the frontier of this interface of LLMs and biomolecules. Recent reviews Zhang et al. 2024 ; Mirza et al. 2024 ; Ramos et al. 2025 ; Wang et al. 2025 provide broader coverage of this expansive area. 2.2 BioAssay data mining BioAssay databases like PubChem and ChEMBL are valuable resources for data mining and have been used to train machine learning models. Sharma et al. 2024 developed a data mining pipeline that compiled and processed 8,415 OXPHOS-related BioAssays from PubChem, identified major OXPHOS inhibitory chemotypes, and trained effective OXPHOS inhibitor classifiers. MolecularGPT ( Liu et al. 2024 ) constructed an instruction tuning dataset by collecting three-shot examples from ChEMBL. MBP Yan et al. 2023 created a multi-task pretraining dataset with labels from BioAssays to address label inconsistencies and data scarcity. TwinBooster Schuh et al. 2024 developed a zero-shot model that integrates molecule structures and BioAssay descriptions for molecular property prediction. 2.3 Structure-based ligand design Molecule design approaches play a role in the hit-finding and lead optimization tasks of early-stage drug discovery. The goal of hit finding is to identify pharmacologically active molecules for a target of interest to serve as starting points for development. Given availability of a 3D structure model for a protein target, structure-based virtual screening methods can be applied for hit finding, such as large-scale docking of pre-enumerated molecule libraries. Alternatively, de novo design approaches Bohacek et al. 1999 ; Spiegel and Durrant 2020 have re-emerged with the advent of deep learning-based generative methods adapted to build molecules with enhanced affinity for a target structure of interest. A variety